HER2+ 유방암

210개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved210 programs
AntibodyLimited DatastaleRochePhase 3

trastuzumab (Herceptin, Docetaxel combined + Trastuzumab +Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase3#monoclonal-antibody#Roche
Trials 30Status Recruiting
AntibodyLimited DatastaleRochePreclinical

trastuzumab (Herceptin, Docetaxel combined with Trastuzumab±Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#monoclonal-antibody#Roche
Trials 30Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, HER2, pyrotinib + pertuzumab/trastuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#SalivaryGlandCarcinoma+2
Trials 30Status Recruiting
AntibodyLimited DatastaleRochePreclinical

trastuzumab (Herceptin, Pertuzumab Plus Trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#monoclonal-antibody#Roche
Trials 30Status Active
AntibodyLimited DatastaleRochePreclinical

trastuzumab (Herceptin, Pyrotinib Plus Trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#monoclonal-antibody#Roche
Trials 30Status Active
ADCStandard DatabasestaleRochePhase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1, T-DM1 and Pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 30Status Recruiting
ADCCurated CorestaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Breast Neoplasms; Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#BioJungboMoa-pick#antibody-drug-conjugate+3
Trials 29Status Recruiting
AntibodyLimited DatastaleZhiyong YuPhase 2

Inetetamab (Inetetamab)

Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#MetastaticBreastCancer+1
Trials 26Status Active
ADCStandard DatabasestaleGileadPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Sacituzumab Govitecan / Trastuzumab Deruxtecan)

Triple Negative Breast Neoplasms; Neoplasm Metastasis · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase2#antibody-drug-conjugate#NeoplasmMetastasis+1
Trials 24Status Recruiting
ADCStandard DatabasestaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#antibody-drug-conjugate#Byondis
Trials 23Status Active
AntibodyLimited DatastaleRegeneronPhase 2

Cemiplimab plus REGN3767 (Cemiplimab plus REGN3767)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 23Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Dual-target CAR-NK cells (Dual-target CAR-NK cells)

Breast Cancer (Advanced/Metastatic); HER2-positive Breast Cancer · Malignant Glioma

#MalignantGlioma#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 23Status Recruiting
ADCStandard DatabasestaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, HER2,trastuzumab deruxtecan± pertuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SalivaryGlandCarcinoma+2
Trials 23Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Tislelizumab)

Breast Cancer; Neoadjuvant Therapy · Breast Cancer

#BreastCancer#ADC#Approved#antibody-drug-conjugate#NeoadjuvantTherapy+1
Trials 17Status Active
ADCStandard DatabasestaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, T-Dxd + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#antibody-drug-conjugate#HER2+BreastCancer+1
Trials 17Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 17Status Active
AntibodyLimited DatastaleALX Oncology Inc.Phase 2

ALX148 (Evorpacept, Evorpacept (ALX148))

Breast Cancer, Metastatic · Breast Cancer, Metastatic

#BreastCancerMetastatic#Antibody#Phase2#monoclonal-antibody#BreastCancer+2
Trials 15Status Recruiting
AntibodyLimited DatastaleRochePhase 1

trastuzumab (Herceptin, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab)

Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm · Advanced Breast Carcinoma

#AdvancedBreastCarcinoma#Antibody#Phase1#monoclonal-antibody#AdvancedMalignantSolidNeoplasm+1
Trials 15Status Discontinued
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR T cells (4SCAR T cells)

Breast Cancer · Autoimmune Diseases

#AutoimmuneDiseases#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 14Status Recruiting

3 / 11 pages

← PreviousNext →